NOVEL REGULATORS OF THE IFN/GAMMA MHC CLASS II PATHWAY

IFN/γ MHC II 类通路的新型调节剂

• 批准号: 2011099
• 负责人: DEBRA J TAXMAN
• 金额: $ 0.54万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-08-17 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/2011099
• 关键词: MHC class II antigen; biological signal transduction; cell line; cytokine receptors; flow cytometry; gene expression; genetic library; genetic regulation; immunoregulation; interferon gamma; molecular cloning; transfection

Upregulation of IFN-gamma and MHC class II expression has been studied in tumor models and is found to be effective for the control of a number of types of cancer. Treatment with IFN-gamma, the main inducer of MHC class II,can promote tumor rejection by activating immune responses. The purpose of this proposal is to identify genes which are essential for the induction of MHC class II gene expression by IFN-gamma. This will be accomplished by using gene complementation to determine the defect in G2A and G3A mutant cell lines, both of which are - selectively defective in IFN- gamma induction of class II-associated genes, but not in the IFN- gamma induction of the classical pathway. As a complementary approach, an antisense library will be used to identify additional genes selectively required for MHC class II induction by IFN- gamma. This work should promote the treatment of cancer through the identification of potential targets for the enhancement of tumor rejection by immunotherapy.

IFN-γ 和 MHC II 类表达的上调 在肿瘤模型中进行研究并发现可有效控制 多种类型的癌症。 IFN-γ治疗， MHC II类主要诱导剂，可促进肿瘤排斥 激活免疫反应。该提案的目的是 识别诱导 MHC II 类必需的基因 IFN-γ 的基因表达。这将通过使用来完成 基因互补以确定 G2A 和 G3A 的缺陷 突变细胞系，两者都 - IFN 选择性缺陷 - γ 诱导 II 类相关基因，但不在 IFN- 中 经典途径的伽马诱导。作为补充 方法，反义库将用于识别额外的 IFN-选择性诱导 MHC II 类所需的基因 伽玛。这项工作应该通过以下方式促进癌症的治疗 识别增强肿瘤的潜在靶点 免疫疗法产生排斥反应。